FOLFOX/Bevacizumab mit oder ohne Irinotecan in der first-line Therapie beim metastasierten kolorektalen Karzinom. Eine randomisierte Phase II Studie (AIO 0209).
The primary objective of this study is to evaluate the efficacy of 5-Fluorouracil (5-FU), oxaliplatin and irinotecan (FOLFOXIRI-Regimen) with bevacizumab versus 5-FU and oxaliplatin (FOLFOX-Regimen) with bevacizumab in patients with metastatic colorectalcancer. Secondary objectives are safety and tolerability of the treatment as well as theprogression free survival, overall survival, secondary resection rate, quality of life and theprognostic value of and the allocation to the clinical classification of patients. The addition of irinotecan might be more effective in terms of response and survival inbevacizumab insensitive compared to bevacizumab sensitive patients, therefore potentialmarkers (VEGF-A, osteopontin, G-CSF, Ang-2, sVEGFR2, neuropilin, Dll4, CAIX/ HIF1a,etc.) will be evaluated.